The scheduling of MDMA: a pharmacist's perspective.
Riedlinger
J E
JE
D015104:3,4-Methylenedioxyamphetamine / Q000031:analogs & derivatives / Q000494:pharmacology; D000662:Amphetamines / Q000494:pharmacology; D000928:Antidepressive Agents / Q000627:therapeutic use; D001321:Autistic Disorder / Q000188:drug therapy; D004335:Drug and Narcotic Control; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D013237:Stereoisomerism; D019966:Substance-Related Disorders; D014481:United States; D014486:United States Food and Drug Administration
D000662:Amphetamines; D000928:Antidepressive Agents; D015104:3,4-Methylenedioxyamphetamine; D018817:N-Methyl-3,4-methylenedioxyamphetamine